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LUX-Lung 7: is there 
enough data for a fi nal 
conclusion?
We read with great interest the 
publication of the LUX-Lung 7 trial,1 
comparing afatinib and gefitinib as 
fi rst-line treatment of patients with 
advanced non-small-cell lung cancer 
with common EGFR mutations. 
As a general rule, in settings where 
more than one drug is available for 
the same treatment indication, a 
direct comparison is always useful. 
However, we believe that in the case 
of LUX-Lung 7, a complete evaluation 
of the comparison would need more 
details than those available in the 
publication in The Lancet Oncology.
First of all, final results of overall 
survival should have been presented 
within the primary publication. Albeit 
progression-free survival has been 
widely accepted as an endpoint in the 
fi rst-line setting of patients positive 
for EGFR mutations [A: correct edit 
of EGFR mutation positive cases?], 
overall survival was chosen by the 
authors as a coprimary endpoint 
together with progression-free 
survival and time-to-treatment failure. 
Therefore [A: edit ok?], a defi nitive 
interpretation of the results should be 
based on all coprimary endpoints. 
Furthermore, the interpretation 
of the time-to-treatment failure 
advantage described in favour of 
afatinib is quite difficult, not only 
because of the open-label design of the 
trial, but also because of the absence of 
details about characteristics of disease 
progression in the two groups. In this 
setting, tyrosine-kinase inhibitors are 
commonly administered beyond the 
formal definition [A: do you mean 
determination or assessment?] of 
progression, especially in asympto-
matic patients with oligo-progressive 
disease.2 The longer time-to-treatment 
failure reported in patients treated 
with afatinib versus gefi tinib compared 
with the negligible diff erence between 
groups in median progression-free 
survival documents a higher amount 
of treatment beyond progression with 
afatinib than with gefi tinib. It would 
be of interest to see if this disparity in 
the administration beyond progression 
could be justified by different 
characteristics of disease at the time of 
progression according to the Response 
Evaluation Criteria in Solid Tumors. For 
instance, a signifi cant diff erence in the 
proportion of symptomatic patients, 
as well as a significant difference in 
the number of progressing metastatic 
sites, or in the volumetric burden 
of progression, would represent 
a reasonable explanation for the 
time-to-treatment failure diff erence. 
Unfortunately, this information 
was not available in the publication. 
Additionally, the diff erence in median 
progression-free survival in favour of 
afatinib was very small (0·1 months) 
and clinically negligible.
In conclusion, based on the 
LUX-Lung 7 data published to date, it 
seems to us premature to claim that 
afatinib has definitely proven to be 
superior to gefi tinib in this setting.
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